New figures released by the European Union (EU) reveal a significant surge in the value of pharmaceutical trade across the…
Read More
Filspari Secures Landmark FDA Approval for Focal Segmental Glomerulosclerosis (FSGS) in Adults and Pediatric Patients Aged Eight and Above
Travere Therapeutics has achieved a significant milestone in the treatment of rare kidney diseases with the U.S. Food and Drug…
Read More
FDA Issues Complete Response Letter to Replimune’s RP1 for Advanced Melanoma
The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Replimune Group’s Biologics License Application…
Read More
Regeneron Pharmaceuticals and Telix Pharmaceuticals Forge Strategic Alliance to Advance Precision Oncology Through Radiopharmaceutical Innovation
Regeneron Pharmaceuticals and Telix Pharmaceuticals have announced a significant partnership aimed at accelerating the development and commercialization of novel radiopharmaceutical…
Read More
AbbVie Secures Up to $745 Million in Pain Pipeline Deal with Chinese Biopharma Haisco
AbbVie, a global biopharmaceutical giant, has finalized a significant strategic collaboration with Haisco Pharmaceutical Group, a prominent Chinese biopharmaceutical company.…
Read More
Gan & Lee Pharmaceuticals Secures Key South Korean Partnership for Bofanglutide Development and Commercialization
Gan & Lee Pharmaceuticals has announced a significant licensing agreement with JW Pharmaceutical, granting the South Korean biopharmaceutical company exclusive…
Read More
Bristol Myers Squibb and Oxford BioTherapeutics Forge Alliance to Pioneer Novel T-Cell Engager Therapies for Solid Tumors
Bristol Myers Squibb (BMS) and Oxford BioTherapeutics (OBT) have announced a significant strategic alliance aimed at discovering and developing a…
Read More
Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers – Pharmaceutical Technology
The landscape of oncology drug development is undergoing a profound transformation, increasingly centered on precision immunotherapies where biomarker-defined patient populations…
Read More
Roche and C4 Therapeutics Forge Strategic Alliance to Pioneer Degrader-Antibody Conjugates for Novel Cancer Therapies
Roche and C4 Therapeutics Forge Strategic Alliance to Pioneer Degrader-Antibody Conjugates for Novel Cancer Therapies Roche, a global pharmaceutical giant,…
Read More
Emerging therapies bring hope for frail HNSCC patients unfit for standard treatment – Pharmaceutical Technology
The global burden of head and neck squamous cell carcinoma (HNSCC) is on an upward trajectory, with an estimated increase…
Read More
